Provided by Tiger Trade Technology Pte. Ltd.

Quasi-New Stocks

664.56
+11.591.77%
Number of Gainers:106
Number of Losers:52
Number of Flat:9
PE:- -
High:676.31
Open:652.87
Low:652.87
Close:652.87
Volume:189.68M
Turnover:5.17B
Market Cap:497.26B
Float Cap:359.13B

Loading ...

Defence Therapeutics Eases Terms on 800,000 Warrants to Boost Investor Uptake

TIPRANKS
·
Mar 21

Kaltura CEO Makes Bold Insider Move With Fresh Stock Purchase

TIPRANKS
·
Mar 21

Major Insider Move at AppLovin Sends Strong Signal to Investors

TIPRANKS
·
Mar 21

Top Serina Therapeutics Executive Makes Notable Stock Move

TIPRANKS
·
Mar 21

Beijing Sub-Center: Bathed in Warm Sunlight, Clear Waters and Blue Skies, Flowers in Full Bloom

Deep News
·
Mar 21

Morning in Sichuan: A Harvest in Spring

Deep News
·
Mar 21

AppLovin Director Eduardo Vivas Disposes of USD 9,589,865 in Common Shares

Reuters
·
Mar 21

Spring Outing by Student Dong Jiayao from Class N505, Supervised by Teacher Zhu Hongmei

Deep News
·
Mar 21

Class N802 Kong Ziling

Deep News
·
Mar 21

ZipRecruiter CEO Ian H. Siegel Disposes of USD 139,896 in Common Shares

Reuters
·
Mar 21

ZipRecruiter EVP and Chief People Officer Amy Garefis disposes of USD 6,492 in common shares

Reuters
·
Mar 21

ZipRecruiter EVP and Chief Legal Officer Ryan T. Sakamoto disposes of USD 6,400 in common shares

Reuters
·
Mar 21

ZipRecruiter President and interim CFO David Travers disposes of USD 59,852 in common shares

Reuters
·
Mar 21

Femasys Amends Financing Terms and Issues New Warrants

TIPRANKS
·
Mar 21

BRIEF-Femasys Enters Omnibus Amendment And Consent Agreement On March 19, 2026 - SEC Filing

Reuters
·
Mar 21

Eterna Therapeutics Faces Nasdaq Delisting Risk After Notice

TIPRANKS
·
Mar 21

Femasys Inc - Amendment Removes Share Combination Event Adjustment in Notes and Warrants Effective Dec 31, 2025 - SEC Filing

THOMSON REUTERS
·
Mar 21

Femasys issues 16,378,563 unregistered Series D-1 warrants at $0.58 exercise price

Reuters
·
Mar 21

AN2 Therapeutics Reprices Stock Options to Enhance Retention

TIPRANKS
·
Mar 21

MaxCyte Faces Nasdaq Noncompliance Over Minimum Bid Price

TIPRANKS
·
Mar 21